Literature DB >> 12559800

Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120.

S Karle1, Y Nishiyama, H Taguchi, Y-X Zhou, J Luo, S Planque, C Hanson, S Paul.   

Abstract

Amino acid residues 421-436 constitute a comparatively conserved determinant of gp120 that participates in the binding of host cell CD4 receptors by HIV-1. We compared the immunogenicity of synthetic Cys-gp120 (421-436) conjugated to KLH via the N terminal Cys residue (KLH-I) and gp120 (421-436) extended at its N terminus with a 15 residue tetanus toxoid T cell epitope (T-I) in non-autoimmune mice (BALB/cstrain) and Fas-defective autoimmune mice (MRL/lpr strain). Both immunogens elicited high titer Abs detected as the binding to gp120 (421-436) conjugated to bovine serum albumin (BSA-I) immobilized in ELISA plates. Abs from KLH-I immunized mice displayed binding to full-length gp120 but the Abs from T-I immunized mice did not. Proteins unrelated in sequence to gp120 did not bind the Abs. Soluble I and T-I failed to compete with immobilized BSA-I for binding to anti-KLH-I Abs, whereas these peptides inhibited anti-T-I Ab binding by BSA-I (rank potency order: BSA-I > T-I >> I). These results indicate the influence of the carrier protein on the specificity of Abs to synthetic I. Low level BSA-I and gp120 binding Abs were detected in sera from non-immunized MRL/lpr mice. Similar Ab binding titers and specificity profiles were evident in MRL/lpr and BALB/c mice following immunization with KLH-I and T-I, indicating that pre-existing immunity to gp120 in the former strain does not influence the magnitude or specificity of the Ab response. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559800     DOI: 10.1016/s0264-410x(02)00504-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Authors:  Gopal Sapparapu; Stephanie A Planque; Yasuhiro Nishiyama; Steven K Foung; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

2.  Constant domain-regulated antibody catalysis.

Authors:  Gopal Sapparapu; Stephanie Planque; Yukie Mitsuda; Gary McLean; Yasuhiro Nishiyama; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-09-04       Impact factor: 5.157

3.  Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection.

Authors:  Stephanie Planque; Maria Salas; Yukie Mitsuda; Marcin Sienczyk; Miguel A Escobar; Jason P Mooney; Mary-Kate Morris; Yasuhiro Nishiyama; Dipanjan Ghosh; Amit Kumar; Feng Gao; Carl V Hanson; Sudhir Paul
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

Review 4.  Back to the future: covalent epitope-based HIV vaccine development.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama; Miguel Escobar; Carl Hanson
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

5.  Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods.

Authors:  Isamu Tsuji; Shuji Sato; Kentaro Otake; Takahiro Watanabe; Hiroko Kamada; Tomofumi Kurokawa
Journal:  MAbs       Date:  2012-09-24       Impact factor: 5.857

6.  Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.

Authors:  Stephanie A Planque; Yukie Mitsuda; Yasuhiro Nishiyama; Sangeeta Karle; Stephane Boivin; Maria Salas; Mary-Kate Morris; Mariko Hara; Guangling Liao; Richard J Massey; Carl V Hanson; Sudhir Paul
Journal:  J Immunol       Date:  2012-10-22       Impact factor: 5.422

Review 7.  Catalytic antibodies to HIV: physiological role and potential clinical utility.

Authors:  Stephanie Planque; Yasuhiro Nishiyama; Hiroaki Taguchi; Maria Salas; Carl Hanson; Sudhir Paul
Journal:  Autoimmun Rev       Date:  2008-04-29       Impact factor: 9.754

8.  Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.

Authors:  Yasuhiro Nishiyama; Stephanie Planque; Yukie Mitsuda; Giovanni Nitti; Hiroaki Taguchi; Lei Jin; Jindrich Symersky; Stephane Boivin; Marcin Sienczyk; Maria Salas; Carl V Hanson; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

9.  A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein.

Authors:  Hanna C Kelker; Vincenza R Itri; Fred T Valentine
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

10.  CD4 binding determinant mimicry for HIV vaccine design.

Authors:  Yasuhiro Nishiyama; Stephanie Planque; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  Front Immunol       Date:  2012-12-17       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.